Bacillus Calmette-Guérin (BCG) shortages and the fragile BCG supply chain have created a bladder cancer treatment vacuum.

Superficial bladder cancer does recur despite bacillus Calmette–Guérin (BCG) instillations—currently the most effective prophylactic therapy. Antifibrinolytic agents seem to enhance the efficacy of ...

Intravesical instillation of bacillus Calmette-Guérin (BCG) is most effective in the long term when selected as initial prophylactic treatment to prevent recurrence of superficial bladder cancer, ...

The phase 3 ALBAN trial tested atezolizumab plus BCG in BCG-naïve patients with high-risk, non-muscle-invasive bladder cancer (NMIBC).

Use of 2 sequential induction courses of BCG for high-risk NMIBC rather than standard induction with maintenance therapy showed an excellent response rate. A novel strategy for using bacillus Calmette ...

Intravesical immunotherapy with BCG is standard of care for patients with non-muscle-invasive bladder cancer, although the clinical response rate is only 50–70%. New research published in Science ...

At ESMO 2025, AstraZeneca reported that Imfinzi plus BCG therapy reduced the risk of recurrence or death by 32% in patients ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

The 2025 ESMO annual meeting featured a urothelial carcinoma proffered paper session and a presentation by Dr. Maria De ...

The approval was based on data from a phase 3 trial in adults with BCG-unresponsive, high-risk, NMIBC with CIS with or without papillary tumors following transurethral resection. The Food and Drug ...

Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasive urothelial carcinoma of the ...